ReviewBreast cancer research : BCR2014
Biology of breast cancer in young women.
Review in Breast cancer research : BCR, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to 2 registered trials, which are not on this map. Cited by 247 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Tumor Mutational Patterns and Infiltrating Lymphocyte Density in Young and Old Patients With Breast Cancer
Randomized Trial of Universal vs. Guideline-directed Germline Testing Among Young Adults With Cancer
Who cites it
247 citing papers in PubMed, 2 syntheses or guidelines pooled it.
- The Requirements for Setting Up a Dedicated Structure for Adolescents and Young Adults with Cancer-A Systematic Review.Current oncology (Toronto, Ont.) · 2025Pooled it
- Safety of fertility preservation techniques before and after anticancer treatments in young women with breast cancer: a systematic review and meta-analysis.Human reproduction (Oxford, England) · 2022Pooled it
- Initial ribociclib plus endocrine therapy for HR+/HER2- advanced breast cancer in pre- and postmenopausal Chinese women: Primary results from a phase 2 randomized study.Cancer medicine · 2024Trial
- Impact of Age on Clinical Outcomes and Efficacy of Adjuvant Dual Anti-HER2 Targeted Therapy.Journal of the National Cancer Institute · 2022Trial
- Long-Term Outcomes With Pharmacological Ovarian Suppression During Chemotherapy in Premenopausal Early Breast Cancer Patients.Journal of the National Cancer Institute · 2022Trial
- Updated Overall Survival of Ribociclib plus Endocrine Therapy versus Endocrine Therapy Alone in Pre- and Perimenopausal Patients with HR+/HER2- Advanced Breast Cancer in MONALEESA-7: A Phase III Randomized Clinical Trial.Clinical cancer research : an official journal of the American Association for Cancer Research · 2022Trial
- Abemaciclib plus fulvestrant in hormone receptor-positive, human epidermal growth factor receptor 2-negative advanced breast cancer in premenopausal women: subgroup analysis from the MONARCH 2 trial.Breast cancer research : BCR · 2021Trial
- Genomic Profiling of Premenopausal HR+ and HER2- Metastatic Breast Cancer by Circulating Tumor DNA and Association of Genetic Alterations With Therapeutic Response to Endocrine Therapy and Ribociclib.JCO precision oncology · 2021Trial
- Age-Associated Four-Gene Prognostic Signature in Breast Cancer.Cancer reports (Hoboken, N.J.) · 2026Article
- Association of Pre-Diagnosis Breast Assessment Practices and Risk Factors with Breast Cancer Stage at Diagnosis: A Single-Center Cross-Sectional Study.Journal of clinical medicine · 2026Article
- Breast Cancer in Women Aged ≤35 Years: A Single-Center Retrospective Comparative Analysis by Age Subgroup.Diagnostics (Basel, Switzerland) · 2026Article
- Pathological characteristics and prognosis of very young patients with early breast cancer: a comparative analysis with older patients.Acta oncologica (Stockholm, Sweden) · 2026Article
- Derivation and external validation of a prognostic nomogram for human epidermal growth factor receptor 2 negative early young breast cancer in women.Discover oncology · 2026Article
- Investigation of Long Non-Coding RNAsNon-coding RNA · 2026Article
- Arabic translation, cross-cultural adaptation, feasibility, acceptability, and initial psychometric evaluation of the hot flushes diary and the hot flush rating scale and diary interference scale (HFRDIS) in young breast cancer survivors.Journal of patient-reported outcomes · 2026Article
- Global patterns and risk factors of breast cancer in women under 35: a population-based study.Breast (Edinburgh, Scotland) · 2026Article
- Breast cancer incidence and survival by subtype, stage at diagnosis and socioeconomic deprivation among young women in the Community of Madrid, Spain.International journal of cancer · 2026Article
- Fertility preservation in young women with breast cancer: a narrative review of effectiveness, oncologic safety, and clinical practice implications.Annals of translational medicine · 2026Review
- Nomogram prediction for breast cancer-specific survival in patients with ERTranslational cancer research · 2026Article
- Baseline Body Composition Characteristics and Overall Survival in Young Women with Breast Cancer: Matched Case-Control Study Nested Within a Cohort.Tomography (Ann Arbor, Mich.) · 2026Article
187 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Breast cancer arising at a young age is relatively uncommon, particularly in the developed world. Several studies have demonstrated that younger patients often experience a more aggressive disease course and have poorer outcome compared to older women. Expression of key biomarkers, including endocrine receptors, HER2 and proliferation markers, appears to be different in younger patients and young women are more likely to harbor a genetic predisposition. Despite these differences, little research to date has focused on the biology of these tumors to refine prognosis, and potentially direct treatment strategies, which remain similar to those offered to older patients. Accumulating evidence suggests the differences in breast stroma in younger patients and changes that occur with pregnancy and breastfeeding likely contribute to the different biology of these tumors. Reproductive behaviors appear to impact the biology of tumors developing later in life. In addition, tumors arising during or shortly following pregnancy appear to exhibit unique biological features. In this review, we discuss our emerging understanding of the biology of breast cancer arising at a young age at both the pathologic and the genomic level. We elucidate the potential role of genomic signatures, the impact of pregnancy and breastfeeding on breast cancer biology, and how even current knowledge might advance the clinical management of young breast cancer patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.